10 results on '"Wajih Zaheer Kidwai"'
Search Results
2. Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma
- Author
-
Sabrina L. Browning, Yuxin Liu, Terri L. Parker, Noffar Bar, Tara Anderson, Madhav Dhodapkar, Stuart Seropian, Stephanie Halene, Mina L Xu, Ria Syam, Elan Gorshein, Autumn DiAdamo, Ashita Talsania, Wajih Zaheer Kidwai, David H. Witt, Victor Chang, Francesca Montanari, Andrew Lischuk, Wei Wei, Andrew Haims, and Natalia Neparidze
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
3. NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022
- Author
-
Elizabeth A. Griffiths, Vivek Roy, Laura Alwan, Kimo Bachiashvili, John Baird, Rita Cool, Shira Dinner, Mark Geyer, John Glaspy, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Anjlee Mahajan, Ryan Miller, Victoria Nachar, Seema Patel, Shiven Patel, Lia E. Perez, Adam Poust, Fauzia Riaz, Rachel Rosovsky, Hope S. Rugo, Shayna Simon, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Ryan A. Berardi, and Lenora Pluchino
- Subjects
Oncology - Abstract
The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient’s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.
- Published
- 2022
4. Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy
- Author
-
Yuxin Liu, Sabrina L. Browning, Jennifer VanOudenhove, Giulia Biancon, Noffar Bar, Terri L. Parker, Tara Anderson, Madhav Dhodapkar, Stuart Seropian, Stephanie Halene, Mina L Xu, Elan Gorshein, Ashita Talsania, Wajih Zaheer Kidwai, David H. Witt, Victor Chang, Francesca Montanari, Andrew Lischuk, Andrew Haims, Wei Wei, and Natalia Neparidze
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
5. Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report
- Author
-
Vanessa Figueroa, Travis J Hollmann, Darren R. Feldman, Anne Capozzi, Brendan John Guercio, Gopa Iyer, Klaus J. Busam, Anthony M. Rossi, Jonathan E. Rosenberg, Komal Jhaveri, Mario E. Lacouture, Yelena Y. Janjigian, Ying-Bei Chen, Soleen Ghafoor, Wajih Zaheer Kidwai, Dean F. Bajorin, Samuel A. Funt, and David N. Assis
- Subjects
Oncology ,medicine.medical_specialty ,Treatment response ,medicine.medical_treatment ,Ipilimumab ,Case Report ,Disease ,lcsh:RC254-282 ,Internal medicine ,Paget Disease ,medicine ,business.industry ,Microsatellite instability ,Immunotherapy ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Immune checkpoint ,Nivolumab ,Extramammary Paget disease ,business ,Immune checkpoint blockade ,medicine.drug - Abstract
Metastatic primary cutaneous extramammary Paget disease (EMPD) is a rare clinical entity with a 5-year survival
- Published
- 2021
6. Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic
- Author
-
Elizabeth A. Griffiths, Martha Wadleigh, Pamela S. Becker, Mark B. Geyer, Peter Westervelt, Avyakta Kallam, Sumithira Vasu, Rita Cool, Ivana Gojo, Rachel P. Rosovsky, Laura M Alwan, Anna Brown, Dwight D. Kloth, Lia Perez, Gary H. Lyman, Peter T. Curtin, Hope S. Rugo, Eric H. Kraut, Kimo Bachiashvili, Wajih Zaheer Kidwai, Sudipto Mukherjee, and Vivek Roy
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy ,business.industry ,Anemia ,medicine.medical_treatment ,Thrombopoietin mimetics ,Cancer ,Context (language use) ,Neutropenia ,medicine.disease ,Article ,03 medical and health sciences ,Haematopoiesis ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Pandemic ,medicine ,030212 general & internal medicine ,business - Abstract
Hematopoietic growth factors, including erythrocyte stimulating agents (ESAs), granulocyte colony-stimulating factors, and thrombopoietin mimetics, can mitigate anemia, neutropenia, and thrombocytopenia resulting from chemotherapy for the treatment of cancer. In the context of pandemic SARS-CoV-2 infection, patients with cancer have been identified as a group at high risk of morbidity and mortality from this infection. Our subcommittee of the NCCN Hematopoietic Growth Factors Panel convened a voluntary group to review the potential value of expanded use of such growth factors in the current high-risk environment. Although recommendations are available on the NCCN website in the COVID-19 Resources Section (https://www.nccn.org/covid-19/), these suggestions are provided without substantial context or reference. Herein we review the rationale and data underlying the suggested alterations to the use of hematopoietic growth factors for patients with cancer in the COVID-19 era.
- Published
- 2021
7. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020
- Author
-
Anna Brown, Rita Cool, Martha Wadleigh, Raajit K. Rampal, Vivek Roy, Ivana Gojo, Sumithira Vasu, Kelly Westbrook, Lenora A. Pluchino, Adam Poust, Ryan Miller, Dwight D. Kloth, Laura Alwan, Sepideh Shayani, Gary H. Lyman, Daniel J. Landsburg, Hope S. Rugo, Jennifer Keller, Shiven B. Patel, Peter T. Curtin, Shira Dinner, Rachel P. Rosovsky, Lia Perez, Pamela S. Becker, Jennifer L. Burns, Ashley Hicks, Elizabeth A. Griffiths, Peter Westervelt, Avyakta Kallam, Eric H. Kraut, Kimo Bachiashvili, Wajih Zaheer Kidwai, and Sudipto Mukherjee
- Subjects
medicine.medical_specialty ,Organizations, Nonprofit ,MEDLINE ,Appropriate use ,Hematopoietic Cell Growth Factors ,Medical Oncology ,Drug Costs ,Risk Factors ,Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Drug approval ,Humans ,Chemotherapy-Induced Febrile Neutropenia ,Intensive care medicine ,Biosimilar Pharmaceuticals ,Drug Approval ,Oncologists ,business.industry ,United States Food and Drug Administration ,Biosimilar ,medicine.disease ,United States ,Cancer treatment ,Oncology ,Practice Guidelines as Topic ,Education, Medical, Continuing ,business ,Febrile neutropenia - Abstract
Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.
- Published
- 2020
8. Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction
- Author
-
Anne C. Chiang, Naralys Sinanis, Kathleen Uscinski, Jane Kanowitz, Wajih Zaheer Kidwai, Kevin A. Vest, Jeffrey Orell, Charles S. Fuchs, Jessica Lake, Kerin B. Adelson, Catherine A. Lyons, Kert D. Sabbath, Lisa Shomsky Bsn Mba, Abe Lopman, Johanna LaSala, Debra S. Brandt, Harold Tara, Jeremy S. Kortmansky, Monica Fradkin, Rogerio Lilenbaum, Constance Engelking, and Arthur Lemay
- Subjects
Male ,Quality management ,Quality Assurance, Health Care ,media_common.quotation_subject ,MEDLINE ,Cancer Care Facilities ,Medical Oncology ,03 medical and health sciences ,0302 clinical medicine ,Patient satisfaction ,Nursing ,Neoplasms ,Physicians ,Surveys and Questionnaires ,Health care ,Medicine ,Humans ,Quality (business) ,030212 general & internal medicine ,media_common ,Quality of Health Care ,Academic Medical Centers ,Oncology (nursing) ,business.industry ,030503 health policy & services ,Health Policy ,Quality Improvement ,Clinical trial ,Oncology ,Patient Satisfaction ,Health Care Surveys ,Female ,0305 other medical science ,business ,Quality assurance - Abstract
Purpose: Many US academic centers have acquired community practices to expand their clinical care and research footprint. The objective of this assessment was to determine whether the acquisition and integration of community oncology practices by Yale/Smilow Cancer Hospital improved outcomes in quality of care, disease team integration, clinical trial accrual, and patient satisfaction at network practice sites. Methods: We evaluated quality of care by testing the hypothesis that core Quality Oncology Practice Initiative measures at network sites that were acquired in 2012 were significantly different after their 2016 integration into the network. Clinical and research integration were measured using the number of tumor board case presentations and total accruals in clinical trials. We used Press-Ganey scores to measure patient satisfaction pre- and postintegration. Results: Mean Quality Oncology Practice Initiative scores at Smilow Care Centers were significantly higher in 2016 than in 2012 for core measures related to improvement in tumor staging ( z = 1.33; P < .05), signed consent and documentation plans for antineoplastic treatment ( z = 2.69; P < .01; and z = 2.36; P < .05, respectively), and appropriately quantifying and addressing pain during office visits ( z = 2.95; P < .05; and z = 3.1; P < .01, respectively). A total of 493 cases were presented by care center physicians at the tumor board in 2017 compared with 45 presented in 2013. Compared with 2012, Smilow Care Center clinical trial accrual increased from 25 to 170 patients in 2017. Last, patient satisfaction has remained at greater than the 90th percentile pre- and postintegration. Conclusion: The process of integration facilitates the ability to standardize cancer practice and provides a platform for quality improvement.
- Published
- 2018
9. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018
- Author
-
Craig Sussman, Griselda Zuccarino-Catania, Sajid A. Khan, Wajih Zaheer Kidwai, Jin He, Paul F. Engstrom, Pamela L. Kunz, Al B. Benson, Emily K. Bergsland, Jennifer R. Eads, Terence Wong, Manisha H. Shah, Leonard B. Saltz, Paul T. Fanta, Jonathan Whisenant, Jordan Berlin, Julie Ann Sosa, Jennifer L. Burns, Christopher H. Lieu, Boris W. Kuvshinoff, Jennifer A. Chan, Fouad Kandeel, Daniel M. Halperin, Whitney S. Goldner, Nikolaos A. Trikalinos, James C. Yao, Matthew H. Kulke, Thorvardur R. Halfdanarson, Ndiya Ogba, Jonathan R. Strosberg, Venu G. Pillarisetty, Nataliya Uboha, Gregory P. Kalemkerian, Thomas J. Giordano, Lawrence S. Blaszkowsky, and Martin J. Heslin
- Subjects
Oncology ,Adult ,medicine.medical_specialty ,Adrenal Gland Neoplasms ,Neuroendocrine tumors ,Medical Oncology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Advanced disease ,Humans ,Adrenal tumors ,Societies, Medical ,Gastrointestinal tract ,Adult patients ,Adrenal gland ,business.industry ,Delivery of Health Care, Integrated ,Distant metastasis ,medicine.disease ,United States ,Neuroendocrine Tumors ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,business - Abstract
The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland tumors, pheochromocytomas, and paragangliomas. Management of NETs relies heavily on the site of the primary NET. These NCCN Guidelines Insights summarize the management options and the 2018 updates to the guidelines for locoregional advanced disease, and/or distant metastasis originating from gastrointestinal tract, bronchopulmonary, and thymus primary NETs.
- Published
- 2018
10. Standardizing goals of care (GoC) documentation for new patients with metastatic disease
- Author
-
Wajih Zaheer Kidwai, Jennifer Pyle, Constance Engelking, and Anne C. Chiang
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,media_common.quotation_subject ,Cancer ,Disease ,medicine.disease ,Documentation ,Oncology ,Family medicine ,medicine ,Quality (business) ,Treatment decision making ,National standard ,business ,media_common - Abstract
26 Background: Executing GoC discussions is an established national standard, underpins high quality patient-centered cancer care and ensures that patients participate actively in treatment decision-making. Capturing key aspects of those discussions in electronic documentation can be challenging when provider time is limited. This project sought to standardize workflow components to enable provider capacity to meet a GoC standard that ≥75% of patients presenting with metastatic cancer have a GoC discussion by their third visit as evidenced by retrievable documentation (EMR format and location). Methods: Baseline data describing provider: patient GoC interactions with eligible patients was obtained and presented. Providers reached consensus on a consistent timing, location and content for electronic GoC documentation. Patient assessment parameters for identifying patients needing GoC discussions were generated, a procedure outlining documentation expectations and facilitative tools were developed. Clinicians were educated on their roles in the process. A variety of quality improvement tools were utilized in project execution (e.g. focus groups, process mapping, cause-effect diagraming, pareto and control charting). Results: See table. Conclusions: Despite time constraints in a busy practice, the ≥75% target set for retrievable GoC documentation was exceeded within the 9-month project timeframe. Providers improved their documentation with familiarity and experience over time. Compliance with documentation location and use of smart phrases were not fully realized, likely due to the short timeframe for adoption of all elements of project aims. Continued improvement is expected as providers become more comfortable with the process and additional facilitative strategies are further integrated including expanding nursing assessment of patients' GoC needs, dedicating time in scheduling templates, Epic alert builds and utilizing Palliative Care Team assist for patients deemed uncomfortable with GoC discussions.[Table: see text]
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.